Literature DB >> 5470087

Glucose and insulin secretory response patterns following diet and tolazamide therapy in diabetes.

J R Turtle.   

Abstract

Glucose and insulin secretory response patterns during glucose tolerance tests were determined in 28 maturity-onset diabetics, and the sequential effects of diet and a sulphonylurea, tolazamide, were assessed. Untreated diabetics showed hyperglycaemia, increased serum immunoreactive insulin response patterns, delayed insulin release, and relative insulin deficiency. Diet alone partially corrected the hyperglycaemia and serum immunoreactive insulin response but had no effect on the delayed insulin release or relative insulin deficiency. Tolazamide plus diet restored all values towards normal. The net effect of maintenance tolazamide therapy was to (1) restore the insulin secretory response pattern to normal, (2) reduce total pancreatic insulin output, and (3) improve the efficiency of insulin secretion. The results suggest that there is a rational basis for the use of sulphonylurea in all maturity-onset diabetics, including patients with mild carbohydrate intolerance and those who are apparently controlled by diet alone.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5470087      PMCID: PMC1701755          DOI: 10.1136/bmj.3.5723.606

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  CLINICAL EFFECTS OF A NEW, POTENT, NON-TOXIC SULFONYLUREA (TOLAZAMIDE).

Authors:  E H GRINNELL; T G SKILLMAN; R BARSE; C L MOLLER
Journal:  Curr Ther Res Clin Exp       Date:  1964-07

2.  LONG-TERM OBSERVATIONS ON ORAL HYPOGLYCEMIC AGENTS IN DIABETES; THE EFFECT OF CARBUTAMIDE AND TOLBUTAMIDE.

Authors:  H BERNHARD
Journal:  Diabetes       Date:  1965-02       Impact factor: 9.461

3.  Ultrastructural changes in islets of the rat produced by tolbutamide.

Authors:  J R WILLIAMSON; P E LACY; J W GRISHAM
Journal:  Diabetes       Date:  1961 Nov-Dec       Impact factor: 9.461

4.  Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia.

Authors:  C J Glueck; R I Levy; D S Fredrickson
Journal:  Diabetes       Date:  1969-11       Impact factor: 9.461

5.  Biochemical studies of "prediabetes".

Authors:  H T Ricketts; R A Cherry; L Kirsteins
Journal:  Diabetes       Date:  1966-12       Impact factor: 9.461

6.  "What is inherited--what is added" hypothesis for the pathogenesis of diabetes mellitus.

Authors:  E Cerasi; R Luft
Journal:  Diabetes       Date:  1967-09       Impact factor: 9.461

7.  Islet-cell metabolism during insulin release. Effects of glucose, citrate, octanoate, tolbutamide, glucagon and theophylline.

Authors:  W Montague; K W Taylor
Journal:  Biochem J       Date:  1969-11       Impact factor: 3.857

8.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.

Authors:  H S Seltzer; E W Allen; A L Herron; M T Brennan
Journal:  J Clin Invest       Date:  1967-03       Impact factor: 14.808

9.  CLINICAL STUDIES OF TOLAZAMIDE AND TOLBUTAMIDE: COMPARATIVE EFFECTIVENESS OF CONTROL OF DIABETES MELLITUS.

Authors:  C S RENNIE; D O ANDERSON
Journal:  Can Med Assoc J       Date:  1963-09-28       Impact factor: 8.262

10.  Clinical experience with the oral antidiabetic compound, tolazamide.

Authors:  J B McKendry; K F Gfeller
Journal:  Can Med Assoc J       Date:  1967-03-04       Impact factor: 8.262

View more
  8 in total

1.  Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone.

Authors:  E Bonora; P Moghetti; M Querena; M Zenere; V Cacciatori; F Tosi; D Travia; G Zoppini; M Muggeo
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

Review 2.  Insulin and oral hypoglycaemic agents. I. Physiological and clinical pharmacological aspects.

Authors:  H D Breidahl; G C Ennis; F I Martin; J R Stawell; P Taft
Journal:  Drugs       Date:  1972       Impact factor: 9.546

3.  Glucose tolerance, plasma insulin and lipids in diabetic subjects before and after treatment with a new sulfonylurea compounds, Ro 6-4563.

Authors:  P Berchtold; P Björntorp; A Gustafson; A Jonsson; S E Fagerberg
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

4.  The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.

Authors:  P O Bitzén; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus.

Authors:  J W Doar; M E Thompson; C E Wilde; P F Sewell
Journal:  Br Med J       Date:  1976-02-28

Review 6.  Oral hypoglycaemic agents. An update.

Authors:  A C Asmal; A Marble
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

Review 7.  Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

Authors:  A Melander; P O Bitzén; O Faber; L Groop
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 8.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.